Hysterectomy and surgical menopause Archive

Vasomotor symptoms, consisting of hot flashes and night sweats, affect 80% of women during the menopause transition and beyond. In May 2023, the FDA approved fezolinetant (Veozah) as the first nonhormonal medication designed specifically for vasomotor symptoms. Other medications deemed effective for hot flashes are prescribed off-label. They include selective serotonin reuptake inhibitors, oxybutynin, and gabapentin. But these drugs may lead to troublesome side effects. Women interested in hot flash relief should ask their clinicians for options that take into account their other symptoms.

There are a number of skin conditions that can affect the vulva. Sometimes the products a woman uses every day can irritate the skin or provoke an allergic reaction.

Women are disproportionately affected by conditions that cause chronic pain, but they sometimes have difficulty getting a definitive diagnosis as to what is causing their pain and may be less likely to receive appropriate treatments even when they do.

Breast cancer survival rates have markedly improved over the past several decades, driven by improved treatments. Less intensive chemotherapy can often be used, and immunotherapy and targeted drugs enable doctors to tailor treatment combinations to each woman. Women with metastatic breast cancer are often living many years because of new treatments that extend their lives. To improve outcomes, women with early-stage breast cancer should seek a multidisciplinary care team, in which many different specialists work in collaboration.

A 2023 study suggests that women who have used menopausal hormone therapy are significantly more likely to develop gastroesophageal reflux disease (GERD).

Vaginitis encompasses several conditions that inflame or infect the vagina, including bacterial vaginosis, yeast infection, sexually transmitted infections, and atrophic vaginitis. Women should see a primary care clinician or gynecologist to properly diagnose and treat the problem.

Pregnancy and reproductive complications, including high blood pressure, diabetes, pre-eclampsia, infertility, and stillbirth, are linked with higher cardiovascular risks in affected women many years later. Such complications affect 5% to 10% of pregnancies and are rising as obesity rates increase and more women postpone pregnancy. Ongoing preventive care and screenings are crucial for women who experienced pregnancy complications to monitor blood pressure, cholesterol, and blood sugar levels and treat any irregularities aggressively.

In May 2023, the FDA approved fezolinetant (Veozah), a nonhormonal drug specifically designed to reduce the frequency and severity of hot flashes in women. Potential side effects include liver damage, abdominal pain, diarrhea, insomnia, or back pain.

The U.S. Preventive Services Task Force released updated draft guidelines in May 2023 proposing that women at average risk of breast cancer be screened every other year starting at age 40.